10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $151.7 million versus the consensus estimate of $158.84 million.

GUIDANCE:

10x Genomics sees FY2024 revenue of $640-660 million, versus the consensus of $639.6 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.